ClinicalTrials.gg
RecruitingNCT06569758Updated Feb 11, 2026

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

A Phase 1 interventional study of GenSci098 and GenSci098 Placebo in Safety, Tolerability and GenSci098, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Planned enrollment
20th of 45
76 · median 64
Started
2024
with 7 others
Phase 1
6 of 55
3 open now
Primary completion
2027-09
later than 17 of 27 live
Registered
28th of 55
by date
Lead sponsor
1 of 55
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 20th largest by planned enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2024, is one of 6 in phase 1, reaches primary completion later than 17 of the 27 other live ones, and was the 28th registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)

Read the detailed description

To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)

03

Conditions studied

  • Safety
  • Tolerability
  • GenSci098
  • Thyroid Eye Disease (TED)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of signing the form (ICF): aged between 18 and 75 years (inclusive).
  2. Diagnosed by the physician as having active TED associated with Graves' disease (GD), based on clinical and laboratory test results, with a CAS ≥ 3 (on the 7-point scale) for the most severely affected eye at screening and baseline.
  3. Onset of active symptoms and signs of TED (including one or more of the following: redness of conjunctiva, swelling of conjunctiva (chemosis), redness of eyelids, swelling of eyelids, swelling of caruncle or plica, spontaneous retrobulbar pain, and pain on attempted upward or downward gaze) within 12 months prior to the screening visit.
  4. Positive for thyroid stimulating hormone receptor antibodies (TRAb) at screening.
  5. Moderate to severe TED (impacting the quality of life, requiring intervention but not threatening vision), usually with at least 2 of the following manifestations: (1) eyelid retraction width ≥ 2 mm, (2) moderate or severe soft tissue involvement, (3) proptosis ≥ 3 mm above normal for race and gender, (4) inconstant or constant diplopia.
  6. Participants must be euthyroid with the underlying disease under control, or have mild hypo- or hyperthyroidism at screening. (Only applicable to Part 1)
  7. Participants must have normal thyroid function or hyperthyroidism due to GD at screening. (Only applicable to Part 2)
  8. No prior treatment with antithyroid medications and/or thyroid hormone replacement therapy, or having taken antithyroid medications and/or thyroid hormone replacement therapy on a stable dose, or having not been treated with antithyroid medications and/or thyroid hormone replacement therapy due to intolerable side effects.
  9. Anyone who will not be required to need or receive any immediate or planned surgical ophthalmological intervention, corrective surgery or orbital irradiation during the study.
  10. Female participants must meet one of the following conditions to be eligible for the study:

    1. Infertile, defined as surgical sterilization (hysterectomy, bilateral salpingectomy, bilateral tubal ligation, or bilateral oophorectomy) at least 6 weeks prior to administration or menopausal (spontaneous amenorrhea ≥ 12 months which is not caused by underlying diseases and confirmed by serum follicle stimulating hormone [FSH] level ≥ 40 mIU/mL).
    2. Fertile female participants agree, from the start of the screening visit until 300 day after the last dose, to consistently and correctly use one of the following acceptable methods of effective :

      1. Complete abstinence (based on the participant's preference and usual lifestyle).
      2. Use of oral contraceptives (estrogen and progesterone), and being on a stable dose of the same contraceptive medication for at least 3 months prior to study treatment.
      3. Injectable or implantable hormonal contraception, or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception with similar efficacy (failure rate \< 1%), such as a hormonal vaginal ring or transdermal hormonal contraception. 4) Vasectomized partner, with the procedure performed at least 6 months ago.
  11. Male participants must meet one of the following criteria to be eligible for the study:

1) agree to use a condom plus an effective method of contraception (i.e., hormonal contraception initiated at least 30 days prior to administration; or placement of an IUD or IUS) when engaging in sexual activity with a female partner of from the start of the screening visit until 24 weeks after the last dose and refrain from donating sperm during this period.

2) agree to practice abstinence from the start of the screening visit until 24 weeks after the last dose.

3) have had a vasectomy at least 6 months prior to study treatment. 12. Voluntarily sign the ICF and be able to understand and comply with the study's treatment regimen and assessments until the end of the study

Exclusion criteria

Exclusion Criteria:

  1. Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 or more lines on the Snellen chart or standard logarithmic chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months.
  2. Corneal injury not relieved by medical management.
  3. Improvement in CAS of ≥ 2 points within 1 month prior to screening or between screening and baseline.
  4. Decrease in proptosis of ≥ 2 mm within 1 month prior to screening or between screening and baseline.
  5. Previous orbital irradiation or surgery for TED.
  6. Use of any (either intravenous or oral) with a cumulative dose equivalent to ≥ 1 g of methylprednisolone for TED within 4 weeks prior to screening (discontinued steroid eye drops arepermitted).
  7. Use of steroids for conditions other than TED within 4 weeks prior to screening (topical steroids for dermatological conditions and inhaled steroids are permitted).
  8. Drug therapy with biologics or peptides, including teprotumumab, rituximab, or tocilizumab, within 6 months or 5 half-lives of the drug (whichever is longer) prior to screening.
  9. Use of any non-steroidal agents within the 3 months prior to screening.
  10. Pre-existing ophthalmic disease or disease (other than TED) that, in the judgment of the investigator, would preclude study participation or complicate interpretation of study results.
  11. History of hyperthyroidism not caused by GD (e.g., toxic adenoma or toxic multinodular goiter), and/or current or previous history of thyroid storm. (Only applicable to Part 2)
  12. History of radioiodine treatment or thyroidectomy within 6 months prior to first dose. (Only applicable to Part 2)
  13. Individuals who cannot abstain from smoking/tobacco products from the screening period to the end of the study.
  14. Any known allergy to the components of the product or analogues or previous allergic reactions to monoclonal antibodies.
  15. Known history /diagnosis of .
  16. Acute/chronic infection within 2 weeks prior to screening.
  17. Participation in another clinical trial within 3 months before screening (except those who did not receive any intervention), or within 5 half-lives of the study drug in other clinical trials (whichever is longer), or concurrent enrollment in another clinical trial.
  18. Those with prolonged interval in 12-lead results (> 450 ms for males, > 460 ms for females) or abnormalities in other 12-lead ECG parameters at screening that, in the investigator's judgment, may affect trial participation;
  19. (ALT) or aspartate aminotransferase (AST) levels > 3 times the , or total (TBIL) or alkaline phosphatase (ALP) > 2 × ULN, blood creatinine (Cr) ≥ 1.5 times the ULN at screening.
  20. Positive blood pregnancy test, or lactating women at the time of screening.
  21. Positive for virus antibody (HCV Ab), antibody (HIV Ab), Treponema pallidum particle agglutination (TPPA) test, or surface antigen (HbsAg) at screening.
  22. History of recreational drug use or substance abuse or positive drug screening results at screening.
  23. Any medical (including other clinically significant abnormal laboratory test parameters) or other conditions that the investigator believes might affect the conduct of the clinical trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    GenSci098

    Drug: GenSci098

  • Placebo comparator
    GenSci098 Placebo

    Drug: GenSci098 Placebo

Interventions

  • DrugGenSci098

    subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.

  • DrugGenSci098 Placebo

    In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, multiple doses of GenSci098 and GenSci098 Placebo will be given.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG]).

    Time frame: SAD Part: 169 days, MAD Part: 281 days

Secondary outcomes

  1. PK parameters after single and multiple subcutaneous doses of GenSci098: maximum concentration at steady state (Cmax,ss);

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  2. PK parameters after single and multiple subcutaneous doses of GenSci098: minimum concentration at steady state (Cmin,ss);

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  3. PK parameters after single and multiple subcutaneous doses of GenSci098: time to maximum concentration at steady state (Tmax,ss);

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  4. PK parameters after single and multiple subcutaneous doses of GenSci098: average concentration at steady state (Cav,ss);

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  5. PK parameters after single and multiple subcutaneous doses of GenSci098: area under the concentration-time curve at steady state (AUC0-τ,ss);

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  6. PK parameters after single and multiple subcutaneous doses of GenSci098: apparent clearance CL/F

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  7. PK parameters after single and multiple subcutaneous doses of GenSci098: half life t1/2,

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  8. Incidences of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs), and titer of ADA.

    Time frame: SAD Part: 169 days, MAD Part: 281 days

Other outcomes

  1. Changes from baseline in serum inflammatory cytokines including interleukin (IL)-6

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  2. Changes from baseline in serum inflammatory cytokines including interleukin IL-8,

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  3. Changes from baseline in serum inflammatory cytokines including monocyte chemotactic protein 1 (MCP-1)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  4. Changes from baseline in serum inflammatory cytokines including interleukin IL-4

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  5. Changes from baseline in serum inflammatory cytokines including interleukin IL-10

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  6. Changes from baseline in serum inflammatory cytokines including interleukin IL-12

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  7. Changes from baseline in serum inflammatory cytokines including interleukin IL-13

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  8. Changes from baseline in serum inflammatory cytokines including interleukin IL-17

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  9. Changes from baseline in serum inflammatory cytokines including interleukin IL-23

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  10. Changes from baseline in serum inflammatory cytokines including interleukin IL-1β

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  11. Changes from baseline in serum inflammatory cytokines including soluble interleukin-1 receptor antagonist (sIL-1RA)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  12. Changes from baseline in serum inflammatory cytokines including interferon γ (IFN γ)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  13. Changes from baseline in serum inflammatory cytokines including transforming growth factor β (TGF β)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  14. Changes from baseline in serum inflammatory cytokines including tumor necrosis factor α (TNF α)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  15. Changes from baseline in serum inflammatory cytokines including Chemokine(C-X-C Motif)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  16. Changes from baseline in serum inflammatory cytokines including Ligand 10 (CXCL-10

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  17. Change from Baseline in proptosis of the study eye,amount of protrusion of the eye from the orbital rim measured by Hertel exophthalmometer.

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  18. Change from Baseline in CAS value of the study eye,composed spontaneous retrobulbar pain, pain on attempted upward or downward gaze,redness of eyelids,redness of conjunctiva,swelling of caruncle or plica,swelling of eyelids,swelling of conjunctiva.

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  19. Change from Baseline in diplopia,Diplopia assessment will be performed using the Gorman score

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  20. Changes from baseline in GO-QoL.

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  21. Changes from baseline in serum thyrotropin receptor antibody (TRAb),

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  22. Changes from baseline in thyroid-stimulating antibody (TSAb)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  23. Changes from baseline in serum total triiodothyronine (T3)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  24. Changes from baseline in serum total thyroxine (T4)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  25. Changes from baseline in serum free triiodothyronine (FT3)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  26. Changes from baseline in serum free thyroxine (FT4)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

  27. Changes from baseline in serum thyroid-stimulating hormone (TSH)

    Time frame: SAD Part: 169 days, MAD Part: 281 days

07

Study locations

1 of 1 sites recruiting
  • Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medication
    Shanghai, Shanghai Municipality 200011, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 26, 2024
StartActual
Sep 24, 2024
Primary completionEst.
Sep 2, 2027
CompletionEst.
Dec 13, 2027
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06569758
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Sep 24, 2024
Primary completion
Sep 2, 2027 (estimated)
Completion
Dec 13, 2027 (estimated)
Last update
Feb 11, 2026

Study contacts

Jun Yan
Contact
yanjun01@genscigroup.com
+8615800359085
Huifang Zhou, PHD
principal investigator · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion